Today’s stock pick update – Open Now

Learn More Wake Up on Monday and Do THIS… Go to your inbox and open my email… Because… every weekend...I do my homework - finding the best recommendation that’s ready for you on Monday morning… It’s fun, it’s exciting - and it happens week after week.(Ad) Click Here to Get My Next Bullseye Trade IBM Shares Soar After Announcing Spin-Off Of Its IT Infrastructure Unit

Jobless claims came in worse than expected, totaling 840,000 last week in another sign that the spike in job growth over the summer has cooled. Initial jobless claims fell by just 9,000 in the week ending October 3, as the prior week’s figure was revised higher by 12,000, the Labor Department reported. Continuing claims fell to 11 million in the week ended September 26. “The stubbornly high level of claims may already be starting to reflect the large corporate job cuts an... Read More

Ocular Therapeutix Inc (NASDAQ: OCUL): Ocular Therapeutix shares are up more than 2% today after the biopharma company announced topline Phase 1 clinical trial results for its OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). “The results of the Phase 1 clinical trial provide an early look at the safety, tolerability, durability, and poten... Read More

Should you buy TRV’s value proposition? One of the segments of this sector that I think is interesting – and that doesn’t get as much attention is the Insurance industry. Companies that provide insurance products – life insurance, property and casualty, auto, health, and so on – certainly are sensitive to economic cycles, since the average consumer is unlikely to take out new insurance policies if they are already being forced to tighten their belts as much as possible to get by. On the commercial side, one of t... Read More

Featured Stock Aileron Therapeutics, Inc. (ALRN) – Buy Price: $1.65 or better Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company’s lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial fo... Read More

Other Top Stories Facebook removes fake accounts linked to conservative group Drive-thru dominates even as dine-in restrictions ease Antibody drugs are no cure but seem promising for COVID-19 West Virginia site chosen for high-speed travel facility Czech Republic tops record infection surge in Eastern Europe

Trend Following Picks Aileron Therapeutics, Inc. (ALRN) – Buy Price: $1.65 or better NeoGenomics, Inc. (NEO) – Buy Price: $40.00 or better American Lithium Corp. (LIACF) – Buy Price: $1.30 or better Aspira Women’s Health Inc. (AWH) – Buy Price: $3.50 or better VivoPower International PLC (VVPR) – Buy Price: $11.50 or better All Picks

Reversal Picks ION Geophysical Corporation (IO) Buy Target $2.06 Sell Target $2.47 MV Oil Trust (MVO) Buy Target $2.72 Sell Target $3.02 Antero Resources Corporation (AR) Buy Target $3.35 Sell Target $3.84 SOS Limited (SOS) Buy Target $2.27 Sell Target $2.84 GEE Group, Inc. (JOB) Buy Target $1.42 Sell Target $1.83 All Picks

Low Price Stock Picks Amplify Energy Corp. (AMPY) AgeX Therapeutics, Inc. (AGE) HEXO Corp. (HEXO) Ring Energy, Inc. (REI) Express, Inc. (EXPR) All Picks

Already subscribed to our premium service? Click here to Login. Not a TradersPro subscriber yet? Learn More About TradersPro Here - Learn The # 1 Key To Successful Stock Investing Profits

This email was sent to phanphuongthanh89.822152@blogger.com  by TradersPro Investiv, LLC 265 N. Main | Ste. D #283 Kaysville | UT | 84037 Unsubscribe or Mange which emails you get from TradersPro   All trading carries significant risk. Please see our full risk disclaimer. Disclaimers, Terms & Conditions | Privacy Policy Copyright © 2020